Hemolytic Disease of Newborn due to ABO Incompatibility between B Blood Group Mother and A Blood Group Neonate

Routray, Suman Sudha; Mishra, Debasish; Kanungo, Girija Nandini; Behera, Rachita

doi:10.1055/s-0042-1750071

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, early intervention treatment has important clinical significance. ABO hemolytic disease of the newborn (ABO-HDN) always occurs in the offspring of blood group O mother and newborns born to mothers with blood type A or B [5,6]. The pathogenesis of ABO-HDN resulting from ABO incompatibility remains unclear, but it is widely accepted that maternal antibodies directed against fetal erythrocytes due to ABO incompatibility initiate erythrocyte destruction, leading to the release of excessive bilirubin [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

The Diagnostic Potential of the L Score for ABO Hemolytic Disease of the Newborn: Insights from a Cross-Sectional Study

Li,

Deng

2024

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Purpose This study aimed to evaluate the diagnostic efficacy of the L score, a novel scoring system, in distinguishing between ABO hemolytic disease of the newborn (ABO-HDN) and non-hemolytic disease of newborn hyperbilirubinemia (NHDNH). Methods A cross-sectional prospective study was conducted to assess the effectiveness of the L score in distinguishing between ABO-HDN (n = 118) and NHDNH (n = 213). Blood routine examination results were collected, and relevant statistical analyses were performed to identify clinically significant parameters. Binary logistic regression analysis was employed to assess the relationship between the L score and the development of these conditions, considering relevant variables. Results Our study identified the red blood cell count, mean corpuscular volume, red blood cell distribution width—coefficient of variation, and red blood cell distribution width—standard deviation as independent risk factors for distinguishing ABO-HDN from other high bilirubinemia conditions (P < 0.001). The L score demonstrated superior predictive performance for ABO-HDN, exhibiting an area under the curve (AUC) of 0.746, with an optimal cutoff value of − 3.0816. The RBC-L score exhibited superior predictive performance (z: 5.596, P < 0.0001) compared to the single-factor RBC indicator, indicating its efficacy in accurately identifying the desired outcome. Conclusion The L score represents a valuable tool for predicting neonatal hyperbilirubinemia and hemolytic disease, facilitating differentiation, and guiding early intervention for improved outcomes. Further research is warranted to validate and expand the applicability of the L score in clinical practice.

show abstract